Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 19/20 | 1.00 |
| ▸ | F10 | P00742 | 3/20 | 1.00 |
| ▸ | F2 | P00734 | 7/20 | 0.68 |
| ▸ | MTOR | P42345 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL234684 | 0.99 | F7 (0.98) | F7F10F2MTOR | |
| SCHEMBL4239365 | 0.90 | F7 (0.82) | F7F10F2MTOR | |
| SCHEMBL4420144 | 0.87 | F7 (1.00) | F7F10F2 | |
| SCHEMBL13993085 | 0.84 | F7 (0.72) | F7F10F2MTOR | |
| SCHEMBL13855059 | 0.83 | F7 (0.70) | F7F10F2MTOR | |
| SCHEMBL4427050 | 0.81 | F7 (1.00) | F7F10F2 | |
| SCHEMBL4961414 | 0.81 | F7 (0.67) | F7F10F2MTOR | |
| SCHEMBL5674444 | 0.77 | F7 (0.64) | F7F10F2 | |
| SCHEMBL4423265 | 0.76 | F7 (1.00) | F7F10F2 | |
| SCHEMBL13714617 | 0.76 | F7 (0.65) | F7F10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1656158-B1 | LIQUID, AQUEOUS PHARMACEUTICAL COMPOSITION OF FACTOR VII POLYPEPTIDES | NOVO NORDISK HEALTHCARE AG (CH) | 2016-03-09 | — | — | EP | claimed |
| EP-1656158-A2 | LIQUID, AQUEOUS PHARMACEUTICAL COMPOSITION OF FACTOR VII POLYPEPTIDES | Novo Nordisk Health Care AG (CH) | 2006-05-17 | — | — | EP | claimed |
| WO-2005016365-A2 | LIQUID, AQUEOUS PHARMACEUTICAL COMPOSITION OF FACTOR VII POLYPEPTIDES | NOVO NORDISK HEALTH CARE AG (CH) | 2005-02-24 | — | — | WO | claimed |
| EP-1656158-B1 | LIQUID, AQUEOUS PHARMACEUTICAL COMPOSITION OF FACTOR VII POLYPEPTIDES | NOVO NORDISK HEALTHCARE AG (CH) | 2016-03-09 | — | — | EP | disclosed |
| US-20130084274-A1 | Liquid, Aqueous Pharmaceutical Compositions of Factor VII Polypeptides | NOVO NORDISK HEALTH CARE AG (CH) | 2013-04-04 | — | — | US | disclosed |
| US-20130084274-A1 | Liquid, Aqueous Pharmaceutical Compositions of Factor VII Polypeptides | NOVO NORDISK HEALTH CARE AG (CH) | 2013-04-04 | — | — | US | disclosed |
| US-8318904-B2 | Liquid, aqueous pharmaceutical compositions of factor VII polypeptides | NOVO NORDISK HEALTH CARE AG (CH) | 2012-11-27 | — | — | US | disclosed |
| US-8318904-B2 | Liquid, aqueous pharmaceutical compositions of factor VII polypeptides | NOVO NORDISK HEALTH CARE AG (CH) | 2012-11-27 | — | — | US | disclosed |
| US-20120003206-A1 | LIQUID, AQUEOUS PHARMACEUTICAL COMPOSITIONS OF FACTOR VII POLYPEPTIDES | NOVO NORDISK HEALTHCARE A/G (CH) | 2012-01-05 | — | — | US | disclosed |
| US-20120003206-A1 | LIQUID, AQUEOUS PHARMACEUTICAL COMPOSITIONS OF FACTOR VII POLYPEPTIDES | NOVO NORDISK HEALTHCARE A/G (CH) | 2012-01-05 | — | — | US | disclosed |
| US-8026214-B2 | Liquid, aqueous pharmaceutical compositions of factor VII polypeptides | NOVO NORDISK HEALTH CARE AG (CH) | 2011-09-27 | — | — | US | disclosed |
| US-7732405-B2 | Liquid, aqueous pharmaceutical compositions of factor VII polypeptides | NOVO NORDISK HEALTH CARE AG (CH) | 2010-06-08 | — | — | US | disclosed |
| US-7732405-B2 | Liquid, aqueous pharmaceutical compositions of factor VII polypeptides | NOVO NORDISK HEALTH CARE AG (CH) | 2010-06-08 | — | — | US | disclosed |
| US-7732405-B2 | Liquid, aqueous pharmaceutical compositions of factor VII polypeptides | NOVO NORDISK HEALTH CARE AG (CH) | 2010-06-08 | — | — | US | disclosed |
| US-20100056453-A1 | Liquid, Aqueous Pharmaceutical Compositions of Factor VII Polypeptides | NOVO NORDISK HEALTHCARE A/G (CH) | 2010-03-04 | — | — | US | disclosed |
| US-20100056453-A1 | Liquid, Aqueous Pharmaceutical Compositions of Factor VII Polypeptides | NOVO NORDISK HEALTHCARE A/G (CH) | 2010-03-04 | — | — | US | disclosed |
| US-20100056453-A1 | Liquid, Aqueous Pharmaceutical Compositions of Factor VII Polypeptides | NOVO NORDISK HEALTHCARE A/G (CH) | 2010-03-04 | — | — | US | disclosed |
| US-20060205648-A1 | Liquid, aqueous pharmaceutical compositions of factor VII polypeptides | NOVO NORDISK HEALTHCARE A/G (CH) | 2006-09-14 | — | — | US | disclosed |
| EP-1656158-A2 | LIQUID, AQUEOUS PHARMACEUTICAL COMPOSITION OF FACTOR VII POLYPEPTIDES | Novo Nordisk Health Care AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005016365-A2 | LIQUID, AQUEOUS PHARMACEUTICAL COMPOSITION OF FACTOR VII POLYPEPTIDES | NOVO NORDISK HEALTH CARE AG (CH) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205648-A1 | Liquid, aqueous pharmaceutical compositions of factor VII polypeptides | F7, F5, F12 | F7 1/4885F10 16/4885F2 44/4885 |
| US-20120003206-A1 | LIQUID, AQUEOUS PHARMACEUTICAL COMPOSITIONS OF FACTOR VII POLYPEPTIDES | F7, F5, F12 | F7 1/4885F10 15/4885F2 40/4885 |
| US-20100056453-A1 | Liquid, Aqueous Pharmaceutical Compositions of Factor VII Polypeptides | F7, F5, F12 | F7 1/4885F10 15/4885F2 40/4885 |
| US-20130084274-A1 | Liquid, Aqueous Pharmaceutical Compositions of Factor VII Polypeptides | F7, F5, F12 | F7 1/4885F10 15/4885F2 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.